Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of pozelimab + cemdisiran in paroxysmal nocturnal hemoglobinuria
2023-510336-36-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 25
01
Overview
Phase 3, open-label trial of pozelimab and cemdisiran in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent serious adverse events, Severity of treatment-emergent serious adverse events and 5 more. Planned start Nov 2024; status: authorised.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2023-510336-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510336-36-00.